The purpose of this retrospective study is to analyze real-world disease progression inmild-moderate COVID-19 patients with at least one risk factor for serve COVID-19 illnessor death.
This study is a retrospective, real world study, without any intervention in clinical
diagnosis and treatment, and only real world data are collected for analysis.
The investigator will review symptoms, risk factors, and other non-invasive inclusion and
exclusion criteria.
The study will collect and analyze available symptoms, risk factors and SARS-COV-2 Ct
value up to 28 days.
Inclusion Criteria:
- Participants who have a positive SARS-CoV-2 test result.
- Participants who have one or more mild or moderate COVID-19 symptoms.
- Participants who have one or more of the following requirements: ≤7 days from the
first positive test for SARS-COV-2 virus infection to Day 1; ≤5 days from the first
onset of COVID-19 symptoms to Day 1.
- Participants who satisfy one or more than one of the following high risks for
progression to severe COVID-19, including death.
Exclusion Criteria:
- Participants who are diagnosed with severe/critical COVID-19 before Day 1.
- Participants who have SpO2≤93% on room air at sea level or PaO2/FiO2≤ 300, or
respiratory rate ≥30 per minute before Day 1.
- Participants who have received mechanical ventilation before Day 1.
- Participants who have received or plan to receive a SARS-CoV-2 monoclonal antibody
treatment or prevention, or antiviral treatment (including the investigational
treatment) before and during hospitalization.
- Participants who have received convalescent COVID-19 plasma treatment before and
during hospitalization.
Shanghai Pudong Hospital
Shanghai, Shanghai, China
Investigator: Minghua Yu
Minghua Yu
+86-18017821601
minghua_md@fudan.edu.cn
Minghua Yu, Principal Investigator
Shanghai Pudong Hospital